Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

NCT05178511 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

The Diagnosis Was ALK Positive NSCLC
Second Generation ALK-TKI is Resistant
Efficacy of Ensatinib in This Subset of Patients

Interventions

DRUG: Ensartinib

Sponsor

Li Zhang, MD